Gain Therapeutics Reports Positive Phase 1b Data for Parkinson's Drug GT-02287, Plans Phase 2

summarizeSummary

Gain Therapeutics reported positive Phase 1b clinical data for GT-02287 in Parkinson's disease, showing significant biomarker reduction and clinical improvement, leading to plans for a Phase 2 trial in 2H 2026.

check_boxKey Events

• Positive Phase 1b Results for GT-02287

  The company's lead program, GT-02287, completed its initial 90-day Phase 1b dosing, demonstrating positive safety and efficacy signals in Parkinson's disease patients.

• Significant Reduction in Parkinson's Biomarker

  Patients with elevated baseline CSF GluSph showed an average 81% reduction in this key biomarker to normal levels after 90 days of GT-02287 treatment (p<0.05).

• Clinical Improvement in Motor Scores

  Individuals with elevated baseline CSF GluSph also experienced a statistically significant improvement of 6.17 points in MDS-UPDRS Parts II and III scores (p<0.05).

• Progression to Phase 2 Clinical Trial

  Based on these results, Gain Therapeutics plans to initiate a Phase 2 safety and efficacy trial for GT-02287 in Parkinson's disease in the second half of 2026.

auto_awesomeAnalysis

Gain Therapeutics announced positive Phase 1b clinical trial results for its lead Parkinson's disease candidate, GT-02287. The data demonstrated both significant biomarker engagement and clinical improvement, which is a crucial de-risking event for a life sciences company. The reduction in CSF GluSph and the improvement in MDS-UPDRS motor scores, particularly in patients with elevated baseline GluSph, provide strong evidence supporting the drug's disease-modifying hypothesis. This positive outcome directly supports the company's plan to initiate a Phase 2 safety and efficacy trial in the second half of 2026, marking a significant advancement for its pipeline.